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Clopidogrel, a thienopyridine derivative, is a potent antiplatelet drug that inhibits
adenosine diphosphate (ADP)-mediated platelet activation and aggregation by selecti-
vely and irreversibly binding to platelet P2Y12 purinergic receptor (1). Results of a large
clinical trial have demonstrated an overall benefit of clopidogrel over aspirin in the pre-
vention of vascular ischemic events (myocardial infarction, stroke, vascular death) in
patients with a history of symptomatic atherosclerotic disease (2). However, platelet
inhibition by clopidogrel is highly variable, and patients with reduced platelet inhibition
have an increased risk of major cardiovascular events (3, 4).
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To exhibit its antiaggregatory effect, clopidogrel has to undergo intestinal absorp-
tion and cytochrome P450-dependent hepatic metabolism to form an active thiol meta-
bolite (5–7). However, only a small proportion of administered clopidogrel is metabo-
lized by P450 (15 % of total metabolites). Most of clopidogrel is hydrolyzed by esterases
to an inactive carboxylic acid metabolite (SR26334) that accounts for approximately 85 %
of the clopidogrel-related compounds circulating in plasma (5–8).
Food has been reported to affect the bioavailability of clopidogrel and/or its meta-
bolites (9–11). McEwen and coworkers (9) have showed that administration of a single
dose of clopidogrel with food has no effect on the extent of exposure to the primary
inactive metabolite of clopidogrel (SR26334) (90 % CI for AUC ratio was 0.90–1.02 for the
fed/fasting state) and concluded that net absorption of clopidogrel was not significantly
modified by food. However, Cmax was lower in the fed compared to the fasting state by
about 21 %. In a separate study performed by Nirogi and coworkers (10), the effect of
concomitant food intake on the bioavailability of a single oral dose of clopidogrel was
examined by estimating the parent drug clopidogrel in plasma. The pharmacokinetic
(PK) parameters were significantly affected by food intake. Specifically, Cmax and AUC
increased 6.1-fold and 9.2-fold, respectively, under fed conditions compared to fasting
conditions. Similar results have been obtained in a recent study performed by Hurbin et
al. (11). As assessed by AUC and Cmax, single dose administration of clopidogrel with
food resulted in a 6.13-fold (90 % CI, 5.31–7.08) and 4.20-fold (90 % CI, 3.57–4.93) increa-
se in clopidogrel exposure, respectively. In the multiple dose study, the corresponding
values were 3.32-fold (90 % CI, 2.88–3.84) and 2.46-fold (90 % CI; 2.03–2.99).
Due to the substantial effect of food on the pharmacokinetics of clopidogrel, the pre-
sented studies were conducted in fasted and fed states. The objective of the studies was
to compare the bioavailability of two oral formulations of clopidogrel, Clopidogrel 75
mg film-coated tablets (Krka, d.d.), as test formulation, and Plavix® 75 mg film-coated
tablets (Sanofi-Synthelabo Limited), as reference formulation, after single dose adminis-
tration under both fasting and fed conditions. Assessment of bioequivalence was based
upon measurement of plasma concentrations of the parent drug, clopidogrel, using im-
proved methanol-free extraction from plasma and its major (inactive) metabolite, clopi-
dogrel carboxylic acid. The improved methanol-free extraction is crucial for clopidogrel
determination as it prevents any metabolite back-conversion into clopidogrel. The effect
of food on the pharmacokinetics of the two formulations was also examined.
EXPERIMENTAL
Study protocol
Two separate studies were performed to assess the bioequivalence of test and re-
ference products. Bioequivalence assessment was performed under both fasting (Study
I) and fed conditions (Study II).
The clinical part of the fasting study (Study I) was conducted at the MDS Pharma
Services Clinical Research Centre, Saint-Laurent, Montréal, Québec, Canada, and the cli-
nical part of the fed study (Study II) was conducted at the inVentiv Health Clinical Cli-
nical Research Facility, Québec City, Québec, Canada.
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The studies were carried out in compliance with the guidelines of the International
Committee on Harmonisation (ICH) on Good Clinical Practice (GCP) (12), local regu-
latory requirements, the ethical requirements of Directive 2001/20/EC(13) and Directive
2001/83/EC as amended by Directive 2003/63/EC (14) and the principles enunciated in
the Declaration of Helsinki and its revisions (15).
The protocol and informed consent forms (ICFs) of both studies were reviewed and
approved by the Ethics Committee (Institutional Review Board convening at 2350 Cohen
Street, Saint-Laurent, Montréal, Québec, Canada, for the fasting study and at 372 Hol-
land view Trail, Suite 300, Aurora, Ontario, Canada, for the fed study) prior to initiation
of study procedures. Written informed consent was obtained from all subjects before
they underwent any study-specific procedures.
Study population
Healthy, non-smoking adult (age 18–55 years) male volunteers with a body mass in-
dex (BMI) between 18 and 30 kg/m2 were enrolled in the studies. All subjects met the
inclusion criteria and no exclusion criteria described in the protocol and were judged
eligible for enrolment in the studies based on medical and medication histories, demo-
graphic data (including gender, age, race, body weight, height and BMI), vital signs
measurements (blood pressure, heart rate, respiratory rate and body temperature), 12-
-lead ECG, physical examination, urine drug screen, urine cotinine test, alcohol screen
and clinical laboratory tests (hematology, biochemistry, urinalysis, human immunodefi-
ciency virus (HIV) test, hepatitis C (HCV) antibodies, hepatitis B surface antigen (HBsAg)).
Subjects who had donated 50 to 499 mL of blood within 30 days or more than 499 mL
within 56 days prior to the first dose or had participated in another clinical trial within
28 days prior to the first dose were excluded.
In addition, volunteers were instructed to abstain from food and drinks containing
xanthine derivatives or xanthine-related compounds at least 24 hours before dosing and
throughout the period of sample collection in each period; alcohol-based products from
at least 24 hours prior to admission and until the end of sample collection in each pe-
riod; food and beverages containing grapefruit products at least 7 days prior to the first
dose and throughout the study; vitamins at least throughout the confinement period;
medication (including-over-the-counter products) or herbal products at least 7 days pri-
or to the first dose and throughout the study.
A total of 96 and 118 subjects were included in the fasting and fed studies, respec-
tively.
Study design
Both trials were designed as open-label, randomized, single dose, 2-treatment, 2-
-period, 2-sequence crossover bioequivalence studies.
In each period of both studies, subjects were confined to the clinical site from at least
10 hour before to 28 hours after administration of the study drug.
In each study, subjects were randomly assigned to receive a single oral dose of either
the test formulation (Clopidogrel 75-mg film-coated tablets containing 75 mg of clopi-
dogrel (as hydrochloride), manufactured by KRKA, d.d., Novo mesto, Slovenia) or the
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reference formulation (Plavix® 75-mg film-coated tablets containing 75 mg of clopido-
grel (as hydrogensulphate), manufactured by Sanofi-Synthelabo Limited, United King-
dom) during the first period and the alternative formulation during the second period.
In the fasting study, there was a 14-day washout period between the doses. The stu-
dy was dosed in two groups of 48. The two groups were dosed 7 days apart at the same
clinical site following the same protocol requirements and procedures. The fed study
was dosed in one group with doses separated by a washout period of 7 days.
In both studies, study drugs were administered with 240 mL of water (room tem-
perature). Mouth and hand checks were performed after administration of each dose to
ensure that volunteers had ingested all the medication.
In the fasting study, food was restricted at least 10 hours before dosing and 4 hours
post-dose. In the fed study, subjects received a standardized breakfast after a supervised
overnight fast of at least 10 hours. Subjects were required to completely consume their
breakfast within 30 minutes prior to drug administration.
In both studies, water was not permitted from 1 hour before dosing to 1 hour fol-
lowing dosing, but was allowed at all other times. Standard meals were provided at ap-
proximately 4 and 9 hours after dosing, and at appropriate times thereafter. Post-dose
meals were identical for both periods.
During both studies, subjects were required to remain ambulatory or seated for the
first 4 hours after dosing in each period.
Sample collection and processing
Blood samples (6 mL) were collected in blood collection tubes containing EDTA K2
before dosing and at the following times thereafter: 0.167, 0.333, 0.5, 0.667, 0.833, 1, 1.25,
1.5, 2, 3, 4, 5, 6, 8, 12, 16, 24 and 28 hours for the fasting study and 0.250, 0.500, 0.750,
1.00, 1.25, 1.50, 1.75, 2.00, 2.25, 2.50, 2.75, 3.00, 3.50, 4.00, 5.00, 6.00, 7.00, 8.00, 12.0, 16.0,
24.0 and 28.0 hours for the fed study.
Samples were cooled in an ice bath immediately after collection and centrifuged un-
der refrigeration (1500 g, 10 minutes, 4 °C) within 110 minutes of collection. Plasma sam-
ples were divided into 4 aliquots and stored frozen at –20 ± 5 °C within 180 minutes
from the start of centrifugation until assayed in the laboratory of inVentiv Health Cli-
nical, Canada.
Determination of clopidogrel and clopidogrel carboxylic acid (SR 26334) in plasma
Chemicals and materials. – Clopidogrel hydrogen sulphate and clopidogrel-2H3 hyd-
rogen sulphate were purchased from SynFine Research Inc. (Ontario, Canada). Ammo-
nium formate was bought from Fluka (Oakville, Canada). Sodium bicarbonate, formic
acid, acetonitrile (ACN), hexanes and ethyl acetate were obtained from EMD (Toronto,
Canada). Human plasma was bought from Valley Biomedical (Winchester, USA).
Clopidogrel carboxylic acid hydrochloride was purchased from SynFine Research
Inc. (Ontario, Canada) and ticlopidine hydrochloride was purchased from Sigma-Aldrich
(Ontario, Canada).
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Calibration standards and quality control preparation. – Stock solutions of clopidogrel
and clopidogrel-2H3 at a concentration of 100 µg mL–1 and subsequent intermediate
solutions were prepared in acetonitrile for the calibration and quality control sample
preparation.
Clopidogrel carboxylic acid and ticlopidine stock solutions were prepared at a con-
centration of 1 and 0.5 mg mL–1 in methanol, respectively.
For the fasting study, clopidogrel calibration standards were prepared in human
EDTA K2 plasma to obtain final concentrations around 5, 10, 125, 250, 500, 1000, 2000
and 2500 pg mL–1. Quality control samples were prepared in human EDTA K2 plasma at
final concentrations of 15, 187.5, 1250 and 1875 pg mL–1. For the fed study, calibration
standards were prepared around 7.5, 15, 150, 750, 1500, 3000, 6000 and 7500 pg mL–1 and
quality control samples at final concentrations of 22.5, 375, 2625 and 5625 pg mL–1.
For clopidogrel carboxylic acid, the same analytical range was used for the fasting
and fed studies. Clopidogrel carboxylic acid calibration standards were prepared in
human EDTAK2 plasma at final concentrations around 4, 8, 40, 400, 800, 1600, 2400, 3200
and 4000 ng mL–1. Quality controls were prepared at concentrations of 12, 600, 1200 and
2800 ng mL–1.
Extraction method. – Clopidogrel was extracted from human plasma by liquid-liquid
extraction using a methanol-free method. Clopidogrel was extracted by adding 150 µL of
plasma to the internal standard working solution prepared in Milli-Q type water. 1 mL
of sodium bicarbonate buffer 200 mmol L–1 was added to the mixture and mixed
thoroughly. The extraction solvent, a mixture of hexane/ethyl acetate (85:15) was
distributed to each tube. After shaking for 15 minutes and centrifugation for 5 minutes at
1500 g at 4 °C to separate the organic and aqueous phases, the top layer was transferred
to a borosilicate tube and evaporated to dryness. The dry residue was then reconstituted
with mobile phase composed of water/acetonitrile (25:75) and ammonium formate 5
mmol L–1. The pH of the mobile phase was adjusted to 6.0 with formic acid.
The analytical method for the analyte clopidogrel carboxylic acid and its internal
standard ticlopidine was protein precipitation with acetonitrile. Acetonitrile was added
to the 0.050 mL aliquot of human EDTA plasma, mixed well and then centrifuged. A por-
tion of the supernatant was diluted with the mobile phase (Milli-Q type water/metha-
nol (55:45), 1 mmol L–1 ammonium formate) to be injected into the analytical column
and mass spectrometer.
Chromatography and mass spectrometry conditions. – Reverse phase high performance
liquid chromatography was chosen to achieve separation in both assays. An API 4000
triple quadrupole mass spectrometer (AB Sciex, Concord, Ontario, Canada) with the
Analyst 1.4.1 software was used for the detection and data acquisition of all experi-
ments. Positive multiple reaction monitoring (MRM) mode with a TurboIonSpray source
was selected. The HPLC components included a Hewlett Packard 1100 Series solvent
delivery module and a Perkin Elmer Series 200 autosampler.
MRM transitions monitored were 322.2212.2 amu and 327.2217.3 amu for clopi-
dogrel mobile phase was a mixture of Milli-Q type water (25 %), acetonitrile (75 %) and
ammonium formate 5 mmol L–1 pumped at a flow rate of 1 mL min–1. The column used
was a Zorbax SB-C8 75 × 4.6 mm 3.5 µm at room temperature and the injection volume
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was 40 µL. Quantitation was obtained with a calibration curve using the peak area ratio
(analyte/internal standard) and 1/x2weighted linear regression.
MRM transitions monitored were 308.1198.2 amu and 264.2125.1 amu for clopi-
dogrel carboxylic acid and ticlopidine, respectively. Positive ionization using the Turbo-
IonSpray™ was used for determination. The Collision Energy was set at 22 and 44 V for
clopidogrel carboxylic acid and ticlopidine, respectively. The mobile phase was pumped
at a flow rate of 1 mLmin–1 and was a mixture of Milli-Q type water/methanol (55:45), 1
mmol L–1 ammonium formate. Separation was achieved on a Zorbax SB-C18, 4.6 × 50
mm, 5 mm column at room temperature and the injection volume was 20 µL. The same
type of quantitation as clopidogrel was used.
Pharmacokinetic analyses
The pharmacokinetic parameters were calculated for plasma clopidogrel and its car-
boxylic acid metabolite (SR26334).
Cmax, maximum observed concentration, and Tmax, time to reach Cmax, were deter-
mined directly from the plasma concentration data. AUC0-t, area under the plasma con-
centration-time curve from time 0 to the time of the last measurable (non-zero) concen-
tration was calculated using the linear trapezoidal rule. AUC0-inf, area under the plasma
concentration-time curve from time 0 to infinity was calculated as AUC0-t + Ct/Kel, whe-
re Ct was the last non-zero concentration. Kel, elimination rate constant was determined
by linear regression of the terminal phase of the ln concentration-time data. T1/2, elimi-
nation half-life, was calculated as ln 2/Kel. Residual area (%), the percentage of extra-
polated area under the curve, was calculated as (1 – (AUC0-t/AUC0-inf)) × 100.
All pharmacokinetic analyses were performed using PhAST (software developed at
MDS) and Bioequiv (software developed at inVentiv Health Clinical, Canada) for the
fasting and fed studies, respectively.
Statistical analyses
For both clopidogrel and clopidogrel carboxylic acid, the analysis of variance
(ANOVA) was carried out on the ln-transformed PK parameters AUC0-t, AUC0-inf and
Cmax, using SAS® GLM procedure (SAS® for WindowsTM, SAS Institute, Cary, NC, USA).
In the fasting study, which was performed in two groups, the ANOVA model in-
cluded group, sequence, period nested within group, formulation, formulation*group
interaction and subject nested within group*sequence effects. ANOVA model in the fed
study, in which subjects were dosed in one group, included sequence, subject within
sequence, period and treatment as factors.
Each ANOVA included calculations of least squares means (LSM), the difference be-
tween formulation LSM and the standard error associated with this difference. Consis-
tent with the two one-sided tests for bioequivalence, 90 % confidence intervals (CI) for
the ratios were derived by exponentiation of the confidence intervals obtained for the
difference between formulation LSM resulting from the analyses on the ln-transformed
AUC0-t, AUC0-inf and Cmax. Confidence intervals were expressed as percentage relative
to the reference formulation. Finally, the intra-subject variability (ISCV) for the AUC0-t,
AUC0-inf and Cmax parameters were also determined.
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Bioequivalence was assessed for clopidogrel as per standards of 90 % geometric con-
fidence interval for ln-transformed AUC0-t, AUC0-inf and Cmax within the 80.00–125.00 %
interval. Results for clopidogrel carboxylic acid were considered as supportive data.
Furthermore, the impact of food on the pharmacokinetics of clopidogrel and clopi-
dogrel carboxylic acid was also assessed for both formulations by comparing ln-trans-
formed AUC0-t, AUC0-inf and Cmax parameters under fed and fasting conditions using
the two-sample t-test with Satterthwaite approximation. Geometric mean ratios were
estimated and geometric 90 % confidence intervals for ratios were calculated using fast-
ed values as reference. Statistical evaluation was performed using the SAS® TTEST pro-
cedure.
Safety evaluation
Safety was assessed by the monitoring of adverse events (whether elicited by query,
spontaneously reported or observed by the clinical staff) or determined by vital signs
measurements and standard laboratory evaluations (hematology, urinalysis and serum
chemistry). Adverse events were monitored throughout the study until resolution and




Demographic summary, including age, race, height, body weight and BMI of popu-
lations from both studies, is presented in Table I.
In fasting and fed studies, all 96 and 118 subjects, respectively, received at least one
dose of the study medication and comprised the safety population.
92 of the 96 subjects in study I (fasting conditions) and 113 of the 118 subjects in
study II (fed conditions) completed both periods of the study. All subjects that complet-
ed the studies were included in the pharmacokinetic and statistical analyses, except for
subject No. 50 of the fed study, who was excluded from the pharmacokinetic and sta-
tistical analyses of clopidogrel because of a clot at 1.50 h in period 1 that affected the
subject’s Tmax and Cmax. Therefore, the number of subjects included in the analyses was
92 in the fasting study and 112 and 113 for clopidogrel and clopidogrel carboxylic acid,
respectively, in the fed study.
Determination of clopidogrel and clopidogrel carboxylic acid (SR 26334) in plasma
Assessment of the back-conversion of a metabolite in the presence of methanol. – During
preliminary experiments, involving samples of a previous study performed by inVentiv
Health Clinical, in which the original method involving methanol in extraction was us-
ed, irreproducibility of the clopidogrel concentrations determined was observed when
the samples were re-assayed. It was deemed necessary to investigate these discrepan-
cies. The areas investigated pointed to the following conclusions.
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In the original method, clopidogrel was extracted from plasma by liquid-liquid
extraction. Internal standard stock solutions were prepared in methanol, while the work-
ing internal standard solution was prepared in a methanol/water mixture (50:50). Plasma
was added to the internal standard working solution and the extraction buffer (sodium
bicarbonate pH 9.5). The proportion of methanol in this mixture was 3.87 %. As methan-
ol involved in the sample extraction procedure was suspected to cause overestimation of
clopidogrel concentrations in study samples, a series of experiments were conducted with
incurred samples from a previous clinical study. Since the metabolite involved in back-
-conversion was unknown, it was more adequate to use real clinical samples for the ex-
periments. The following experiments using different percentages of methanol and ace-
tonitrile in internal standard solutions were performed to demonstrate the impact of
methanol on the metabolite back-conversion:
A. Internal standard stock solution in methanol, internal standard intermediate solution
in methanol and internal standard working solution in water/methanol (50:50) like
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Table I. Summary of demographic characteristics of the study populations for Study I (fasting conditions)
and Study II (fed conditions)
Category Study I (fasting conditions) Study II (fed conditions)
N 96 118
Age (years)
Mean ± SD 36 ± 8 33 ± 9
Range 18 to 52 18 to 54
Race
Asian 1 (1.0 %) 0
Black 6 (6.3 %) 2 (1.7 %)
Caucasian 89 (92.7 %) 116 (98.3 %)
Other 0 0
Height (cm)
Mean ± SD 174 ± 6 – 174.2 ± 6.4 175 ± 7
Range 161 to 191 162 to 196
Mass (kg)
Mean ± SD 75.6 ± 7.0 81.2 ± 8.3
Range 60.3 to 89.7 63.7 to 99.1
BMI (kg/m2)
Mean ± SD 24.9 ± 1.8 26.4 ± 2.3
Range 20.7 to 27.8 21.5 to 29.9
in the original method for a proportion of methanol of 3.87 % in the plasma, internal
standard working solution and buffer solution mixture.
B. Internal standard stock solution in methanol, internal standard intermediate solution
in methanol and internal standard working solution in water for a proportion of me-
thanol of 0.04 % in the plasma, internal standard working solution and buffer solu-
tion mixture.
C. Internal standard stock solution in methanol, internal standard intermediate solution
in methanol and internal standard working solution in water/acetonitrile (50:50) for
a proportion of methanol of 0.04 % in the plasma, internal standard working solution
and buffer solution mixture.
D. Internal standard stock solution in methanol, internal standard intermediate solution
in acetonitrile and internal standard working solution in water/acetonitrile (50/50)
for a proportion of methanol of 0.0025 % in the plasma, internal standard working
solution and buffer solution mixture.
These solutions were added to the plasma samples and the extraction buffer (sodi-
um bicarbonate at pH 9.5) and the resulting mixtures were kept at room temperature for
0 and 30 minutes prior to extraction and analysis. Results are presented in Table II.
The presence of methanol in the sample extraction procedure enhanced the back-
-conversion of one of clopidogrel metabolites. Overestimation of clopidogrel concentra-
tions increased proportionally with methanol quantity in the extraction process. More-
over, degradation of this metabolite increased with the extraction time as demonstrated
in Table II. It was found that a low proportion (0.04 %) of methanol induced an increase
of approximately 5 % of clopidogrel concentration in 30 minutes (experiments B, C).
However, 0.04 % of methanol induced an increase of clopidogrel concentrations up to 15
% when compared to the experiment with only 0.0025 % of methanol (experiments B, C
vs. experiment D), showing that the amount of methanol must be at a minimum during
the extraction. The improved methanol-free extraction is therefore the method of choice
for clopidogrel measurement in human plasma.
Validation of the method. – Methanol-free extraction for the determination of clopi-
dogrel in human plasma was thus validated in accordance with the Food and Drug Ad-
ministration (FDA) validation guidelines (16). Different parameters were assessed dur-
ing the validation: accuracy and precision, selectivity, sensitivity, analyte and internal
standard recoveries, dilution integrity, matrix effect, hemolysis and lipemic effect, sta-
bilities in matrix and in solution.
In quality control samples, clopidogrel was found to be stable in human EDTA K2
plasma for 739 days at –20 °C, for 23 hours at room temperature and after four freeze-
-thaw cycles. Clopidogrel carboxylic acid was found to be stable for 252 days at –20 °C,
for 26 hours at room temperature and after four freeze-thaw cycles.
In addition, during method validation, clopidogrel stability during sample treat-
ment (prior to the addition of extraction solvent) was evaluated. A pool of real clinical
samples was incubated at room temperature with the internal standard solution prepar-
ed in Milli-Q type water (from an intermediate solution prepared in acetonitrile) and the
extraction buffer (sodium bicarbonate pH 9.5) for 30 and 60 minutes. Results are pre-
sented in Table III.
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It was shown that the assay was highly reproducible when done without methanol.
No changes in clopidogrel concentrations were observed when substituting methanol
with acetonitrile and water in the solutions used prior to study sample extraction while
maintaining all the other extraction steps and reagents unchanged. This indicates that
there was no back-conversion of clopidogrel metabolites with the improved methanol-
-free extraction.
Pharmacokinetic evaluation
Mean clopidogrel and clopidogrel carboxylic acid concentration-time profiles are
presented in Figs. 1 and 2 for the fasting and fed conditions, respectively. Table IV sum-
marizes descriptive statistics for the main pharmacokinetic parameters of clopidogrel
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with 0.0025 % of
methanol (%)
A 3.87 0 950.55 366.5
30 1327.53 39.7 551.5
B 0.04 0 222.68 9.3
30 235.07 5.6 15.4
C 0.04 0 204.53 0.4
30 214.72 5.0 5.4
D 0.0025 0 203.77 N/AP
30 206.36 1.3 1.3
Experiment A, working internal standard (IS) solution in H2O/MeOH (50:50) and IS intermediate solution in
MeOH; Experiment B, working IS solution in H20 and IS intermediate solution in MeOH; Experiment C,
working IS solution in H2O/ACN (50:50) and IS intermediate solution in MeOH; Experiment D, working IS
solution H2O/ACN (50:50) and IS intermediate solution in CAN.
Table III. Impact of incubation time at room temperature during sample extraction on clopidogrel using
improved methanol-free extraction
Clopidogrel concentration (pg mL–1)
Incubation time at r.t. (min)
0 30 60
Average 110.16 110.14 109.21
SD 1.830 3.089 0.170
CV (%) 1.7 2.8 0.2
Difference (%) N/Ap –0.02 –0.85
and clopidogrel carboxylic acid, obtained for the two tested formulations under both
fasting and fed conditions.
As seen from Figs. 1 and 2, the profiles of test and reference formulations show
similar absorption, distribution and elimination under both fasting and fed conditions.
After administration of both test and reference formulations under fasting condi-
tions, clopidogrel was rapidly absorbed, with median Tmax of clopidogrel and carboxylic
acid metabolite occurring within 1 hour after dosing. Mean AUC0-t, AUC0-inf and Cmax of
clopidogrel were 2257.62, 2579.18 and 1106.70 pg mL–1, respectively, for the test formu-
lation and 1909.67, 1983.37 and 981.37 pg mL–1, respectively, for the reference formula-
tion. Mean AUC0-t, AUC0-inf and Cmax of clopidogrel carboxylic acid for the respective
formulations were 6632.39 ngh mL–1, 7105.75 ngh mL–1, 2545.68 ng mL–1 and 6774.74
ngh mL–1, 7229.61 ngh mL–1and 2608.86 ng mL–1.
In the presence of food, absorption was somewhat delayed for both analytes, as in-
dicated by median Tmax of clopidogrel and carboxylic acid metabolite occurring 1.75
hours after administration of the test formulation and 1.50 hours after administration of
the reference formulation. Food substantially increased the rate and extent of clopido-
grel absorption; mean values for AUC0-t, AUC0-inf and Cmax of clopidogrel were 5784.53
pg h mL–1, 5880.63 pg h mL–1 and 3176.73 pg mL–1, respectively, for the test formulation
and 5546.89 pg h mL–1, 5631.20 pg h mL–1 and 3002.99 pg mL–1, respectively, for the re-
ference formulation. Mean AUC0-t, AUC0-inf and Cmax of clopidogrel carboxylic acid for
the respective formulations were 6513.08 ng h mL–1, 6845.59 ng h mL–1, 2284.18 ng mL–1
and 6510.43 ng h mL–1, 6836.09 ng h mL–1 and 2193.73 ng mL–1.
The design of the studies was adequate for determining the pharmacokinetic para-
meters of the test and reference formulations.
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Fig. 1. Mean plasma concentration-time profiles of clopidogrel (left panel; n = 92) and clopidogrel
carboxylic acid (right panel; n = 92) following single-dose administration of test and reference for-
mulations of clopidogrel 75 mg tablets in healthy subjects under fasting conditions (data from Study I).
In both studies, the selection and timing of blood samples were judged appropriate
to adequately characterize the pharmacokinetics of clopidogrel and carboxylic acid me-
tabolite since there was no subject with Cmax being the first point of the concentration-
-time curve and the mean extrapolated portion of the AUC0-inf of clopidogrel and clo-
pidogrel carboxylic acid was very low for the test and reference products under both
tested conditions. Finally, there was no detectable concentration of clopidogrel and car-
boxylic acid metabolite in the pre-dose samples of period 2 in either study, suggesting
that the washout periods in both studies were adequate to allow complete elimination of
the drug before period 2 and to avoid any carryover.
Statistical evaluation
The least squares means ratios as well as the 90 % geometric confidence intervals
for the ratios of ln-transformed AUC0-t, AUC0-inf and Cmax of the test to reference pro-
ducts are presented in Table V.
In both studies, the confidence intervals for AUC0-t, AUC0-inf and Cmax of clopido-
grel were well within the acceptance range of 80.00 to 125.00 %, indicating that the test
formulation was bioequivalent to the reference formulation under both fasting and fed
conditions. Although in terms of the demonstration of bioequivalence, the parent com-
pound, clopidogrel, is essential, results of clopidogrel carboxylic acid, although thera-
peutically inactive, indicate that also metabolic processes occur at a comparable rate and
extent in test and reference formulations, which gives further evidence of equivalence in
in vivo performance.
Intra-subject variability for clopidogrel PK parameters AUC0-t, AUC0-inf and Cmax
was 43.29, 43.52 and 54.63 %, respectively, under fasting conditions and 23.78, 23.52 and
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Fig. 2. Mean plasma concentration-time profiles of clopidogrel (left panel; n = 112) and clopidogrel
carboxylic acid (right panel; n = 113) following single-dose administration of test and reference for-
mulations of clopidogrel 75 mg tablets in healthy subjects under fed conditions (data from Study II).
32.93 %, respectively, under fed conditions. The corresponding values for clopidogrel
carboxylic acid were 8.36, 7.83 and 26.03 % for the fasting conditions and 5.74, 5.79 and
19.68 % for the fed conditions. High intra-subject variability of clopidogrel pharmaco-
kinetic parameters, observed in both studies, confirms the adequate design of the two
studies also with regard to the number of subjects included in the studies. Calculated
intra-subject variability was reasonably low for clopidogrel carboxylic acid.
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Table IV. Pharmacokinetic parameters of clopidogrel and clopidogrel carboxylic acid following single-dose
administration of test and reference formulations of clopidogrel 75 mg tablets in healthy subjects under
fasting (Study I) and fed (Study II) conditions
Parametersa
Study I (fasting conditions)
(n = 92 for clopidogrel and
clopidogrel carboxylic acid)
Study II (fed conditions)
(n = 112c for clopidogrel and n = 113
for clopidogrel carboxylic acid)
Test Reference Test Reference
Clopidogrel
AUC0-t (pg h mL–1) 2257.62 (3482.86) 1909.67 (1575.74) 5784.53 (2675.80) 5546.89 (2704.29)
AUC0-inf (pg h mL–1) 2579.18 (3891.35)d 1983.37 (1649.49)e 5880.63 (2743.19)f 5631.20 (2753.74)f
Residual area (%) 6.63 (7.55)d 6.46 (6.36)e 1.73 (0.91)f 1.75 (0.93)f










Kel (h–1) 0.1398 (0.0806)d 0.1289 (0.0539)e 0.1475 (0.0543)f 0.1475 (0.0515)f
T1/2 (h) 7.11 (6.24)d 6.90 (4.74)e 5.50 (2.33)f 5.39 (2.12)f
Clopidogrel carboxylic acid
AUC0-t (ng h mL–1) 6632.39 (1372.74) 6774.74 (1435.91) 6513.08 (1201.22) 6510.43 (1194.87)
AUC0-inf (ng h mL–1) 7105.75 (1452.37) 7229.61 (1536.30) 6845.59 (1327.37) 6836.09 (1267.02)
Residual area (%) 6.64 (3.98) 6.26 (3.24) 4.69 (1.99) 4.71 (2.07)










Kel (h–1) 0.0816 (0.0201) 0.0821 (0.0188) 0.0953 (0.0158) 0.0964 (0.0167)
T1/2 (h) 9.06 (2.46) 8.89 (2.08) 7.49 (1.32) 7.43 (1.46)
a Arithmetic mean (standard deviation)
b Median (minimum-maximum)
c Subject No. 50 was excluded from the pharmacokinetic and statistical analyses of clopidogrel because of a
clot at 1.50 h in period 1 that affected Tmax of the subject.
d-f AUC0-inf, Residual area, Kel and T1/2 could not be calculated for some subjects. For these parameters, d n = 83,
e n = 86, f n = 111.
Clopidogrel pharmacokinetics varied widely also among subjects. Coefficients of
variation of Cmax and AUC of clopidogrel ranged from 82.51 to 154.27 % in the fasting
state and from 46.26 to 61.03 % in the fed state. Like intra-individual variability, inter-
-individual variability of clopidogrel carboxylic acid was lower; the corresponding rang-
es were 20.44 to 34.30 % and 18.35 to 29.87 %.
Highly variable pharmacokinetics, observed in our clopidogrel studies, are consis-
tent with literature data (4, 17) and have been explained by several factors, including
demographic factors (age and body mass) (4), variability in intestinal drug absorption
(due to polymorphism in the transporter molecule P-glycoprotein, commonly referred to
as ATP-binding cassette protein B1, ABCB1) (17–21) and cytochrome P450-dependent
enzyme activity (CYP3A4 activity, genetic polymorphism in CYP2C19) (21–24). Likely
contributors to this variation in clopidogrel pharmacokinetics include still unidentified
factors (genetic factors, other than CYP2C19 and P-glycoprotein polymorphism, and
nongenetic sources of variation in clopidogrel absorption and metabolism) (4).
Food substantially increased clopidogrel bioavailability from both test and reference
formulations. Specifically, AUC0-t, AUC0-inf and Cmax increased 3.80-fold (90 % CI 3.19,
4.51), 3.32-fold (90 % CI 2.78, 3.97) and 4.71-fold (90 % CI 3.84, 5.78), respectively, for the
test formulation, and 3.63-fold (90 % CI 3.09, 4.25), 3.48-fold (90 % CI 2.97, 4.07) and 4.13-
-fold (90 % CI 3.43, 4.99), respectively, for the reference formulation.
As regards inactive metabolite, food had practically no effect on the extent and rate
of exposure, as indicated by fasting/fed ratios for AUC0-t, AUC0-inf and Cmax 0.99 (90 %
CI 0.94, 1.03), 0.97 (90 % CI 0.92, 1.01) and 0.93 (90 % CI 0.85, 1.00), respectively, for the
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Table V. Summary of the results of statistical analyses of clopidogrel and clopidogrel carboxylic acid comparing
the test formulation with the reference formulation under fasting (Study I) and fed conditions (Study II)
Parameters
Study I (fasting conditions)
(n = 92)
Study II (fed conditions)
(n = 112 for clopidogrel and n = 113
for clopidogrel carboxylic acid)
Ratio of LSM 90 % geometric CI Ratio of LSM 90 % geometric CI
Clopidogrel
AUC0-t 99.71 % 90.08–110.37 % 104.40 % 99.11–109.97 %
AUC0-inf 97.62 %a 87.35–109.09 %a 104.41 %b 99.15–109.94 %b
Cmax 95.00 % 83.82–107.67 % 108.22 % 100.79–116.20 %
Clopidogrel carboxylic acid
AUC0-t 97.98 % 96.00–100.01 % 100.00 % 98.74–101.27 %
AUC0-inf 98.41 % 96.55–100.32 % 99.99 % 98.72–101.27 %
Cmax 97.31 % 91.39–103.61 % 104.79 % 100.38–109.39 %
a n = 86
b n = 111
test formulation, and 0.97 (90 % CI 0.92, 1.01), 0.95 (90 % CI 0.91, 1.00) and 0.86 (90 % CI
0.79, 0.93), respectively, for the reference formulation.
Several factors that may account for the observed effect of food on clopidogrel phar-
macokinetics have been reported (11, 25). In the Question & Answers document issued
by the Committee for Human Medicinal Products (25), the increase in clopidogrel bio-
availability, observed under fed conditions, was hypothesized to be caused by reduced
acidic hydrolysis in the stomach due to limited dissolution of clopidogrel in gastric me-
dia under fed conditions compared to extensive hydrolysis and formation of the inactive
carboxylic acid metabolite under fasting conditions, which reduced the amount of un-
changed clopidogrel available for absorption at the intestinal level. However, recent
tests of in vitro dissolution tests performed by Hurbin and coworkers (11) showed that
clopidogrel was not significantly degraded in a test solution of pH 2.0 (similar to fasted
gastric pH), with no evidence of acidic hydrolysis compared to solutions of pH 4.5 and
6.8. Furthermore, the authors explained the significant increase in unchanged clopido-
grel observed after concomitant administration of clopidogrel with food by a combina-
tion of food effects at the intestinal level (higher clopidogrel solubility and/or reduced
precipitation) and decreased hepatic first-pass metabolism due to increased blood flow
in the fed state. Clopidogrel is a high extraction ratio drug (11) and, hence, the increase
in hepatic blood flow in the fed state is expected to decrease hepatic first-pass metabo-
lism and increase clopidogrel bioavailability.
The effect of food was comparable between the two formulations, as indicated by
the same direction and rank of food impact on the bioavailability (AUC and Cmax) of
both formulations. Furthermore, the effect of food on the pharmacokinetics of clopido-
grel and its carboxylic acid metabolite, as observed in our studies, is consistent with that
previously reported for clopidogrel and its inactive metabolite (9–11), where a signifi-
cant effect of food on clopidogrel bioavailability (AUC and Cmax) was reported (10, 11).
However, there was no food effect on the exposure to the primary metabolite of clopi-
dogrel (SR 26334) (9).
The absence of a substantial food effect observed in our study as well as in the lite-
rature (9) for the inactive clopidogrel carboxylic acid is presumably related to the op-
posing effects of the increased liver blood flow (decreased first pass metabolism to car-
boxylic acid) and increased solubility and/or decreased precipitation of clopidogrel at
the intestinal level (increased fraction of clopidogrel absorbed) under fed conditions.
Safety and tolerability
Adverse events (AEs) were reported in 17 of the 96 subjects and 42 of 118 subjects in
the fasting and fed studies, respectively, who received at least one dose of the study me-
dication (safety population). The most common AEs in the fasting study were headache
(8 subjects; 8.3 %) and dizziness (5 subjects; 5.2 %); the most common AEs in the fed
study were headache (13 subjects; 11.0 %), somnolence (5 subjects; 4.2 %) and dizziness
(5 subjects; 4.2 %). No serious or severe AEs occurred during the two studies.
Of all AEs reported, 5 subjects (5.3 % of the study population receiving test formu-
lation, altogether 11 AEs) experienced at least 1 adverse event that was possibly, pro-
bably, or definitely related to treatment, and 4 subjects (4.3 % of the study population
receiving reference formulation, altogether 8 AEs) experienced at least 1 adverse event
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that was possibly, probably, or definitely related to treatment in the fasting study. In the
fed study, 13 subjects (11.2 % of the study population receiving test formulation, alto-
gether 14 AEs) and 10 subjects (8.7 % of the study population receiving reference for-
mulation, altogether 10 AEs) experienced at least 1 adverse event that was possibly, pro-
bably, or definitely related to treatment.
To summarize, test and reference formulations were well tolerated under both fast-
ing and fed conditions, with no serious adverse events. No relevant differences in safety
profiles were observed between the two formulations.
CONCLUSIONS
Platelet inhibition by clopidogrel is highly variable. A significant component of the
inter-patient differences in responses to clopidogrel is undoubtedly its highly variable
pharmacokinetics. Considering the pronounced food effect and the mentioned high
variability in clopidogrel pharmacokinetics, which has not been fully explained yet, as
well as its substantial inter-patient variability in response, associated with increased risk
for cardiovascular events, additional in vivo testing under fed conditions can provide a
significant contribution in terms of demonstration of comparable safety and efficacy of
the two formulations.
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